15 years of historical data (2011–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
PTC Therapeutics, Inc. trades at 8.8x earnings, 10% below its 5-year average of 9.8x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 63%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.5B | $6.7B | $3.5B | $2.1B | $2.7B | $2.8B | $4.0B | $2.8B | $1.6B | $654M | $371M |
| Enterprise Value | $4.9B | $6.1B | $5.2B | $3.7B | $3.9B | $3.9B | $4.2B | $2.9B | $1.5B | $607M | $238M |
| P/E Ratio → | 8.76 | 9.76 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 3.15 | 3.88 | 4.30 | 2.20 | 3.92 | 5.21 | 10.58 | 9.21 | 6.04 | 3.36 | 4.49 |
| P/B Ratio | — | — | — | — | — | 1951.78 | 8.36 | 4.76 | 4.56 | 4.18 | 3.11 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
PTC Therapeutics, Inc.'s enterprise value stands at 5.6x EBITDA, 21% below its 5-year average of 7.1x. The Healthcare sector median is 13.8x, placing the stock at a 59% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.54 | 6.40 | 3.94 | 5.61 | 7.22 | 11.14 | 9.34 | 5.76 | 3.12 | 2.88 |
| EV / EBITDA | 5.61 | 7.06 | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 5.61 | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
PTC Therapeutics, Inc. earns an operating margin of 50.1%. Operating margins have expanded from -46.9% to 50.1% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 92.9% | 93.0% | 93.6% | 94.0% | 95.0% | 96.0% | 95.2% | 97.6% | -42.2% |
| Operating Margin | 50.1% | 50.1% | -37.5% | -46.9% | -64.0% | -69.5% | -113.4% | -78.6% | -43.7% | -33.1% | -159.7% |
| Net Profit Margin | 39.4% | 39.4% | -45.0% | -66.8% | -80.0% | -97.3% | -115.1% | -82.0% | -48.4% | -40.6% | -171.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -216.7% | -81.4% | -53.2% | -50.5% | -57.2% | -68.0% |
| ROA | 29.7% | 29.7% | -20.2% | -34.8% | -30.7% | -25.3% | -22.9% | -18.3% | -17.0% | -23.9% | -44.6% |
| ROIC | — | — | -32.2% | -39.9% | -35.0% | -31.6% | -48.8% | -39.7% | -44.9% | -100.1% | -491.7% |
| ROCE | 56.8% | 56.8% | -25.0% | -33.9% | -32.8% | -22.3% | -26.0% | -20.6% | -18.3% | -24.3% | -48.7% |
Solvency and debt-coverage ratios — lower is generally safer
PTC Therapeutics, Inc. carries a Debt/EBITDA ratio of 0.5x, which is very conservative (85% below the sector average of 3.1x). The company holds a net cash position — cash of $985M exceeds total debt of $399M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 882.73 | 0.87 | 0.55 | 0.44 | 0.93 | 0.82 |
| Debt / EBITDA | 0.46 | 0.46 | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | 750.80 | 0.44 | 0.07 | -0.21 | -0.30 | -1.12 |
| Net Debt / EBITDA | -0.68 | -0.68 | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -1.81 | -3.40 | -4.92 | -4.35 | -7.66 | -19.31 | -9.21 | -5.32 | -15.96 |
Net cash position: cash ($985M) exceeds total debt ($399M)
Short-term solvency ratios and asset-utilisation metrics
PTC Therapeutics, Inc.'s current ratio of 2.35x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.02x to 2.35x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.35 | 2.35 | 2.35 | 2.02 | 1.71 | 1.87 | 4.44 | 3.30 | 1.92 | 3.04 | 5.27 |
| Quick Ratio | 2.27 | 2.27 | 2.31 | 1.97 | 1.65 | 1.84 | 4.37 | 3.22 | 1.83 | 2.90 | 5.27 |
| Cash Ratio | 2.01 | 2.01 | 1.96 | 1.45 | 1.01 | 1.52 | 3.98 | 2.91 | 1.36 | 2.33 | 4.67 |
| Asset Turnover | — | 0.60 | 0.47 | 0.49 | 0.41 | 0.28 | 0.17 | 0.19 | 0.24 | 0.50 | 0.31 |
| Inventory Turnover | 2.47 | — | 2.47 | 2.14 | 2.05 | 2.04 | 1.01 | 0.63 | 0.79 | 0.43 | — |
| Days Sales Outstanding | — | 38.30 | 71.73 | 62.59 | 81.28 | 74.85 | 67.03 | 66.03 | 93.63 | 75.85 | 110.02 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
PTC Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 11.4% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 11.4% | 10.2% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $88M | $77M | $75M | $72M | $70M | $66M | $59M | $47M | $39M | $34M |
Compare PTCT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| PTCTYou | $5B | 8.8 | 5.6 | — | — | 50.1% | — | — | 0.5 |
| AGIO | $2.3T | -4.2 | — | — | 88.3% | -873.9% | -30.2% | -26.6% | — |
| VRTX | $126B | 32.4 | 26.6 | 39.5 | 86.2% | 39.1% | 22.5% | 22.8% | 0.8 |
| ASND | $14B | -54.7 | — | 278.6 | 85.1% | -18.9% | — | -69.1% | — |
| BBIO | $13B | -17.5 | — | — | 94.4% | -113.3% | — | — | — |
| BMRN | $12B | 34.3 | 18.2 | 16.4 | 77.1% | 16.6% | 5.7% | 7.4% | 1.0 |
| COGT | $6B | -15.2 | — | — | — | — | -73.7% | -66.4% | — |
| MIRM | $5B | -196.4 | — | 87.3 | 80.8% | -4.2% | -8.6% | -5.1% | — |
| FOLD | $4B | -79.8 | 139.5 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
| CRNX | $4B | -8.3 | — | — | 80.1% | -9534.5% | -40.2% | -37.8% | — |
| CORT | $4B | 43.5 | 78.6 | 26.7 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 15 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PTCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonPTC Therapeutics, Inc.'s current P/E ratio is 8.8x. The historical average is 9.8x.
PTC Therapeutics, Inc.'s current EV/EBITDA is 5.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 7.1x.
Based on historical data, PTC Therapeutics, Inc. is trading at a P/E of 8.8x. Compare with industry peers and growth rates for a complete picture.
PTC Therapeutics, Inc. has 50.1% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
PTC Therapeutics, Inc.'s Debt/EBITDA ratio is 0.5x, indicating low leverage. A ratio below 2x is generally considered financially healthy.